Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
Business Wire2d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
pharmaphorum16h
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
FierceBiotech16h
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Le Lézard1d
TRYX Announces Exclusive Partnership with Pro Gamers Group for EU Market
We are thrilled to announce that TRYX has entered into a strategic partnership with Pro Gamers Group, making them the ...
Le Lézard21h
Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...
Metro Weekly8h
Multiple Paths to HIV Prevention: The Power of Choice
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
The Pharma Letter1d
Gilead and Merck tout first weekly oral HIV treatment
have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an ...
pharmaphorum5d
Data sets up 2021 filings for Gilead's twice-a-year HIV drug lenacapavir
namely ViiV Healthcare with cabotegravir and Merck & Co’s islatravir (MK-8591). The 36-patient CAPELLA trial tested lenacapavir in highly treatment-experienced HIV patients who had developed ...